Literature DB >> 29180527

Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Brian T Tsuji1, James Fisher1,2, Raheal Boadi-Yeboah1, Patricia N Holden1, Sanjay Sethi3,4, Melinda M Pettigrew5, Timothy F Murphy6,7,8.   

Abstract

The pharmacodynamic profile of azithromycin against persistent strains of nontypeable Haemophilus influenzae (NTHi) from chronic obstructive pulmonary disease (COPD) patients was characterized. Azithromycin displayed differential concentration-dependent activities (R2 ≥ 0.988); the pharmacodynamic response was attenuated when we compared the "first" and "last" strains of NTHi that persisted in the airways of the same patient for 819 days (the 50% effective concentration [EC50] increased more than 50 times [0.0821 mg/liter versus 4.23 mg/liter]). In the hollow-fiber infection model, NTHi viability was maintained throughout simulated azithromycin (Zithromax) Z-Pak regimens over 10 days.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  azithromycin; macrolide-lincosamide-streptogramin B; nontypeable H. influenzae

Mesh：

Substances：

Year:  2018        PMID： 29180527      PMCID： PMC5786777          DOI： 10.1128/AAC.01995-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Timothy F Murphy
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

2.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

Authors:  K A Rodvold; M H Gotfried; L H Danziger; R J Servi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

Review 5.  Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program.

Authors:  Robert P Rennie; Khalid H Ibrahim
Journal:  Clin Infect Dis       Date:  2005-08-15       Impact factor: 9.079

6.  Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Andrew T Schiffmacher; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2004-04-29       Impact factor: 21.405

7.  Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Authors:  Melinda M Pettigrew; Brian T Tsuji; Janneane F Gent; Yong Kong; Patricia N Holden; Sanjay Sethi; Timothy F Murphy
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.

Authors:  George G Zhanel; Mel DeCorby; Ayman Noreddin; Chris Mendoza; Andrew Cumming; Kim Nichol; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

9.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.

Authors:  Sevim Uzun; Remco S Djamin; Jan A J W Kluytmans; Paul G H Mulder; Nils E van't Veer; Anton A M Ermens; Aline J Pelle; Henk C Hoogsteden; Joachim G J V Aerts; Menno M van der Eerden
Journal:  Lancet Respir Med       Date:  2014-04-15       Impact factor: 30.700

10.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Nancy Evans; Brydon J B Grant; Timothy F Murphy
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245
View more
  2 in total

1.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Authors:  Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.